文献速递淋巴瘤

英国CD19 CAR T治疗大B细胞淋巴瘤患者结局随时间改善

Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
PubMed 文献 · Br J Haematol · 2023-10-17

分析英国726例拟接受CD19 CAR T治疗的复发/难治性大B细胞淋巴瘤患者,比较国家CAR T项目第一年(2019年)与近期(2020-2022年)的结局。近期组在脱落率、无进展生存和总生存方面均显著优于第一年,高等级细胞因子释放综合征和ICU入住减少,结果强调与新型疗法比较时应使用最新临床数据。

要点

  • 近期治疗时代相比第一年,1年PFS为50% vs 32%、1年OS为60% vs 40%,均有显著改善
  • 近期组脱落率17% vs 第一年27%(p=0.001),桥接治疗使用增加且桥接结局改善
  • 高等级细胞因子释放综合征4% vs 9%(p=0.01),ICU入住20% vs 32%(p=0.001)

核心结论

  • 随时间推移,CD19 CAR T治疗复发/难治性大B细胞淋巴瘤的结局显著改善,强调与新型治疗选择比较时应使用最新临床数据。

研究设计与样本

  • 分析英国726例拟接受CD19 CAR T治疗的复发/难治性大B细胞淋巴瘤患者,比较国家CAR T项目第一年(2019年)与近期治疗时代(2020-2022年)的结局。

主要发现

  • 近期组相比第一年,脱落率17% vs 27%(p=0.001),1年无进展生存50% vs 32%(p<0.001),1年总生存60% vs 40%(p<0.001)。
  • 近期组桥接治疗使用增加、桥接结局改善,托珠单抗/糖皮质激素使用增多。
  • 近期组高等级细胞因子释放综合征4% vs 9%(p=0.01),ICU入住20% vs 32%(p=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The success of CD19 Chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL) has been partially offset by toxicity and logistical challenges, which off-the-shelf agents like CD20xCD3 bispecific antibodies might potentially overcome. However, when using CAR T outcomes as the 'standard-of-care comparator̕ for relapsed/refractory (r/r) LBCL, a potential learning curve with implementing a novel, complex therapy like CAR T needs to be considered. To address this, we analysed 726 UK patients intended to be treated with CD19 CAR T for r/r LBCL and compared outcomes between the first year of the national CAR T programme (Era 1; 2019) and the more recent treatment era (Era 2; 2020-2022). We identified significant improvements for Era 2 versus Era 1 in dropout rate (17% vs. 27%, p = 0.001), progression-free survival (1-year PFS 50% vs. 32%, p < 0.001) and overall survival (1-year OS 60% vs. 40%, p < 0.001). We also observed increased use of bridging therapy, improvement in bridging outcomes, more tocilizumab/corticosteroid use, reduced high-grade cytokine release syndrome (4% vs. 9%, p = 0.01) and intensive care unit admissions (20% vs. 32%, p = 0.001). Our results demonstrate significant improvement in CAR T outcomes over time, highlighting the importance of using up-to-date clinical data when comparing CAR T against new treatment options for r/r LBCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Boyle S, Roddie C, O'Reilly M, et al. Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time. Br J Haematol. 2023. PMID: 37848384. doi:10.1111/bjh.19157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。